PhaseBio Pharmaceuticals, Inc. (PHASQ)
OTCMKTS: PHASQ · Delayed Price · USD
0.0133
+0.0012 (9.50%)
Jan 27, 2023, 3:04 PM EST - Market closed
PHASQ has decreased by -99.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
Analyst Consensus: Sell
Analyst Ratings
The average analyst rating for PHASQ stock from 9 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Dec '22 | Jan '23 |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 4 | 4 |
| Sell | 2 | 2 |
| Strong Sell | 3 | 3 |
| Total | 9 | 9 |
Financial Forecast
Revenue This Year
9.61M
from 10.83M
Decreased by
-11.32%
Revenue Next Year
4.75M
from 9.61M
Decreased by
-50.56%
EPS This Year
-1.23
from -2.98
EPS Next Year
-1.10
from -1.23
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
|
2.36M | 320.00K | 10.83M | 9.61M | 4.75M | 25.64M | - | - | - |
| Revenue Growth
|
- | -86.45% | 3,284.69% | -11.32% | -50.56% | 439.86% | - | - | - |
| EPS
|
-1.43 | -3.39 | -2.98 | -1.23 | -1.10 | -1.01 | - | - | - |
| EPS Growth
|
- | - | - | - | - | - | - | - | - |
| No. Analysts | - | - | - | 5 | 5 | 5 | - | - | - |
Revenue Forecast
| Revenue | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| High | 9.8M | 9.7M | 52.3M | n/a | n/a | n/a |
| Avg | 9.6M | 4.7M | 25.6M | n/a | n/a | n/a |
| Low | 9.1M | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| High | -9.6%
| 0.8%
| 1,000.7%
| - | - | - |
| Avg | -11.3%
| -50.6%
| 439.9%
| - | - | - |
| Low | -15.6%
| - | - | - | - | - |
EPS Forecast
| EPS | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| High | -1.13 | -0.42 | -0.37 | -1.13 | -1.22 |
| Avg | -1.23 | -1.10 | -1.01 | -1.07 | -1.17 |
| Low | -1.27 | -1.70 | -1.59 | -1.04 | -1.13 |
EPS Growth
| EPS Growth | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.